## Pharmacologic Therapy for Men and Women Aged 50 Years and Older

Physician Quality Reporting System Data Collec	tion Sh	eet		
			/ /	☐ Male ☐ Female
Patient's Name Practice Medical Record Nun	's Name Practice Medical Record Number (MRN)		Birth Date (mm/dd/yyyy)	Gender
National Provider Identifier (NPI)			Date of Service	
Clinical Information			Billing Information	
Step 1 Is patient eligible for this measure?				
	Yes	No	Code Required on Claim Form	
Patient is aged 50 years and older on date of encounter.			Verify date of birth on claim for	orm.
Patient has a diagnosis of osteoporosis.			Refer to coding specifications document for list of applicable codes. Codes determining a patient's eligibility must be reported on the same claim as	
There is a CPT Code for this visit.				
If <b>No</b> is checked for any of the above, STOP. Do not report a CPT category II code.			the quality code(s) identified below.	
Step 2 Does patient meet or have an accepta for not meeting the measure?	ble reas	son		
Pharmacologic Therapy <sup>1</sup>	Yes	No	Code to be Reported on Line 24 if <i>Yes</i> (or Service Line 24 of El	
Prescribed <sup>2</sup>			4005F	
Not prescribed for one of the following reasons:  • Medical (eg, not indicated, contraindicated, other medical reason)			4005F-1P	
Patient (eg, patient declined, economic, social, religious, other patient reason)			4005F-2P	
System (eg, resources to perform the services not available, other reason attributable to health care delivery system)			4005F-3P	
Document reason here and in medical chart.			If <b>No</b> is checked for <b>all</b> of the a 4005F–8P (Pharmacologic therapy for os prescribed, reason not otherw	teoporosis was not

<sup>&</sup>lt;sup>1</sup>Pharmacologic Therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modules or SERMs (raloxifene).

<sup>&</sup>lt;sup>2</sup>"Prescribed" may include prescription given to the patient for treatment of osteoporosis (as listed above) at one or more encounters during the reporting period, OR documentation that patient is already taking pharmacologic therapy for osteoporosis, as documented in the current medication list.